AMGN (NASDAQ) - Amgen Inc

Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US0311621009
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AMGN (NASDAQ) - Amgen Inc
Market Cap. 116,521m USD
GiC Sector Health Care
GiC Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1983-06-17


Fundamental 2.36
Dividend 8.05
Performance 5y 3.87
Performance TTM -0.22
Relative Performance -4.10
Analysts 3.42
Price / Fair Price TR 1.10
Price / Fair Price DCF todo


Growth TTM -7.08%
CAGR 5y 6.83%
CAGR / Mean Drawdown 5y 0.87
Sharpe Ratio TTM -0.57
Alpha vs SP500 TTM -10.30
Beta vs SP500 5y weekly 0.53
CAPM 7.52%
Average Daily Range % 1.73%
Volatility GJR Garch 1y 22.95%
Max Drawdown 5y 25%
Mean Drawdown 5y 7.9%
Price / SMA 50 -5.42%
Price / SMA 200 -9.75%
Current Volume 1814.5k
Average Volume 2348.7k


Rate TTM 8.14
Yield TTM 3.68%
Div. CAGR 5y 8.01%
Consistency of Dividends all time 100.0%